Company Performance - Bioventus (BVS) has returned 102.5% year-to-date, significantly outperforming the Medical sector, which has returned an average of -5% [3] - The Zacks Consensus Estimate for BVS' full-year earnings has increased by 2.5% over the past quarter, indicating improved analyst sentiment and earnings outlook [7] - Bioventus is part of the Medical - Drugs industry, which has an average return of -11.4% year-to-date, further highlighting BVS's strong performance [9] Industry Context - The Medical sector consists of 1020 individual stocks and is currently ranked 3 in the Zacks Sector Rank [6] - The Medical - Biomedical and Genetics industry, which includes Adagene Inc. Sponsored ADR, has returned -12.3% year-to-date and is ranked 64 out of 501 stocks [5] - Adagene Inc. Sponsored ADR has returned 6.1% year-to-date, indicating it has also outperformed its sector [8]
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?